.png)
.png)
|
Genome&Company Rallies on Expectations for Clinical Progress of GENA-104
According to KG Zeroin’s MP DOCTOR (formerly MarketPoint), shares of Genome&Company, Inc. surged by won 1,300 (20.47%) to close at won 7,650, driven by expectations for the clinical advancement of an immuno-oncology candidate licensed out to a UK partner.
Genome&Company announced that it had completed the supply of clinical trial materials for its immuno-oncology candidate EP0089 (GENA-104) to UK-based Ellipses Pharma Limited and received payment. GENA-104 is a novel immunotherapy targeting CNTN4, first discovered by the company.
The revenue stems from the supply of clinical materials under the licensing agreement signed with Ellipses in February last year. Through this deal, Genome&Company has established an efficient business model that leverages Ellipses’ clinical development capabilities while enabling staged revenue generation.
Under the agreement, Ellipses Pharma will take full responsibility for clinical development, including the upcoming Phase 1 trial. Genome&Company will receive a share of revenues generated from future commercialization of GENA-104 based on a pre agreed percentage.
EP0089 is currently being prepared for Phase 1/2a trials in solid tumor patients in Korea and Australia under Ellipses’ leadership with plans to expand into the U.S. and Europe and enroll approximately 190 patients.
Hong You seok CEO of Genome&Company stated “The completion of this supply demonstrates that our collaboration with Ellipses Pharma is progressing as planned,” adding that “the smooth clinical development of EP0089 will help confirm its potential as a first in class immunotherapy.”
Meanwhile, the company participated in AACR 2026 held in San Diego from April 17 to 22, where it presented research results on three novel ADC pipeline candidates.
ViGenCell Pulls Back After Doubling in a Month
Shares of ViGenCell Inc. fell by won 1,160 (10.48%) to close at won 9,910. The decline appeared to be a correction following a sharp rally rather than being driven by a specific catalyst.
The stock had traded in the won 5,000 range earlier this month but climbed to around won 11,000 over three trading sessions starting April 24, effectively doubling in less than a month. Over the past three months, the stock rebounded from a low of won 4,700 on April 7 to a peak of won 12,400 on April 27, including two consecutive limit-up sessions on April 22 and 23.
The rally was largely attributed to momentum ahead of the ASCO 2026, where ViGenCell plans to deliver an oral presentation of Phase 2 results for its cell therapy candidate VT-EBV-N.
A company official commented, “The recent sharp rise appears to have led to a natural correction phase. There is no particular issue.”
|
Curocell Gains After First Domestic CAR-T Approval in Korea
Shares of Curocell Inc. rose by won 4,000 (6.21%) in after-hours trading to won 68,400, following news of regulatory approval for its chimeric antigen receptor T-cell (CAR-T) therapy.
South Korea’s Ministry of Food and Drug Safety approved the company’s CAR-T therapy, Rimkatoju (anbalcabtagene autoleucel), marking roughly one year since the company filed for approval in December 2024.
This marks the first approval of a domestically developed CAR-T therapy in Korea, signaling a potential structural shift in a market that has largely depended on high cost imported products from global players such as Novartis and Gilead Sciences.
Curocell plans to accelerate its domestic launch following the approval. A company official noted, “As the product is manufactured locally using patients’ own cells we expect faster supply for lymphoma patients.”
